On Tuesday, CervoMed Inc (CRVO) stock saw a decline, ending the day at $2.16 which represents a decrease of $-8.09 or -78.93% from the prior close of $10.25. The stock opened at $2.53 and touched a ...

Fintel reports that on December 10, 2024, D. Boral Capital downgraded their outlook for CervoMed (NasdaqCM:CRVO) from Buy to ...

CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary ...

CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with ...

Fintel reports that on December 11, 2024, Chardan Capital downgraded their outlook for CervoMed (NasdaqCM:CRVO) from Buy to ...

CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a ...

CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b ...

Morgan Stanley double downgraded CervoMed (CRVO) to Underweight from Overweight without a price target saying multiple questions remain for ...

Canaccord lowered the firm’s price target on CervoMed (CRVO) to $12 from $65 and keeps a Buy rating on the shares. The firm said they announced ...

CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet ...

CervoMed on Tuesday said a mid-stage study of its lead program neflamapimod missed its key goals in the degenerative brain disease dementia with Lewy bodies, or DLB.

CervoMed Inc. (NASDAQ:CRVO – Free Report) – Equities researchers at HC Wainwright issued their Q4 2024 earnings estimates for ...